Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. (June 2017)

• Record Type: Journal Article
• Authors: Popat, Sanjay; Mellemgaard, Anders; Reck, Martin; Hastedt, Claudia; Griebsch, Ingolf
• Is Part Of: Future oncology. Volume 13:Number 13(2017)
• Page Start: 1159
• Page End: 1171
• Publication Date: 2017-06
• Subjects: chemotherapy -- immunotherapy -- nintedanib -- nivolumab -- NSCLC -- second-line treatment; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2016-0493
• Languages: English
• ISSNs: 1479-6694

Abstract

Patients & methods: We provide an update to a network meta-analysis evaluating the relative efficacy of nintedanib + docetaxel versus other second-line agents in adenocarcinoma histology non-small-cell lung cancer.Results: Overall similarity of nintedanib + docetaxel versus ramucirumab + docetaxel, and versus nivolumab. Comparing nintedanib + docetaxel with nivolumab, hazards ratio (HR) of overall survival and progression-free survival (PFS) pointed in opposite directions (overall survival: HR: 1.20 [95% credible interval: 0.92–1.58]; PFS: HR: 0.91 [0.68–1.21]). Exploratory subgroup analysis indicated superiority of nivolumab in high PD-L1 expression level subgroups; results were more favorable for nintedanib in all subgroups with low (<1%, <5%, <10%) PD-L1 expression levels – in particular, with regard to PFS.Conclusion: Results demonstrated similar efficacy of nintedanib + docetaxel compared with the new therapeutic options ramucirumab + docetaxel and nivolumab, with potential differences in subgroups according to PD-L1 expression level.